scout

Lisa Nodzon, PhD, APRN, AOCNP

Articles by Lisa Nodzon, PhD, APRN, AOCNP

Panelists discuss the declining role of allogeneic transplant in chronic myeloid leukemia (CML) due to advances in tyrosine kinase inhibitors (TKIs) while emphasizing ongoing challenges related to treatment tolerability, management of advanced disease, and financial toxicity that necessitate continued research and supportive care strategies.

Panelists discuss the importance of monitoring molecular milestones in chronic myeloid leukemia (CML) to guide treatment response and eligibility for treatment-free remission (TFR), emphasizing the multidisciplinary team’s role—including pharmacists and nurses—in supporting adherence, managing adverse effects, and providing individualized patient care.

Panelists discuss the evolving landscape of frontline chronic myeloid leukemia (CML) treatment, highlighting asciminib’s emerging role as a preferred first-line therapy due to its favorable efficacy, tolerability, and potential to simplify treatment selection while supporting long-term goals like deep molecular response and treatment-free remission.

Panelists discuss the critical role of early molecular testing and multidisciplinary collaboration—including pharmacists, nurse practitioners, and physicians—in personalizing chronic myeloid leukemia (CML) treatment, managing adverse effects, and supporting patient adherence to optimize long-term outcomes.

Latest Updated Articles